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OBJECTIVES We have tested whether a genotype-phenotype relationship exists in Brugada syndrome (BS)
by trying to distinguish BS patients with (carriers) and those without (non-carriers) a
mutation in the gene encoding the cardiac sodium channel (SCN5A) using clinical
parameters.
BACKGROUND Brugada syndrome is an inherited cardiac disease characterized by a varying degree of
ST-segment elevation in the right precordial leads and (non)specific conduction disorders. In
a minority of patients, SCN5A mutations can be found. Genetic heterogeneity has been
demonstrated, but other causally related genes await identification. If a genotype-phenotype
relationship exists, this might facilitate screening.
METHODS In a multi-center study, we have collected data on demographics, clinical history, family
history, electrocardiogram (ECG) parameters, His to ventricle interval (HV), and ECG
parameters after pharmacologic challenge with INa blocking drugs for BS patients with (n 
23), or those without (n  54), an identified SCN5A mutation.
RESULTS No differences were found in demographics, clinical history, or family history. Carriers had a
significantly longer PQ interval on the baseline ECG and a significantly longer HV time. A
PQ interval of 210 ms and an HV interval 60 ms seem to be predictive for the presence
of an SCN5A mutation. After INa blocking drugs, carriers had significantly longer PQ and
QRS intervals and more increase in QRS duration.
CONCLUSIONS We observed significantly longer conduction intervals on baseline ECG in patients with
established SCN5A mutations (PQ and HV interval and, upon class I drugs, more QRS
increase). These results concur with the observed loss of function of mutated BS-related
sodium channels. Brugada syndrome patients with, and those without, an SCN5A mutation
can be differentiated by phenotypical differences. (J Am Coll Cardiol 2002;40:350–6)
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Brugada syndrome (BS) presents with malignant ventricular
arrhythmias occurring in the structurally normal heart,
leading to (aborted) sudden death. The hallmark electrocar-
diographic (ECG) feature of the disorder is ST-segment
See page 357
elevation in the right precordial leads (1–3). This ECG
feature may not, however, be consistently present, and
transient normalization of the ST segment is commonly
observed (3,4). Other characteristic ECG features include a
terminal negative T-wave in the right precordial leads and
specific (i.e., left anterior hemiblock, right bundle branch
block) or non-specific (QRS widening) conduction disor-
ders. This phenotype is increasingly recognized as an
inherited trait and is classified among the familial primary
electrical disorders (5).
Mutations in the gene encoding the pore-forming sub-
unit of the cardiac sodium channel, SCN5A, have been
causally linked in patients and families with BS (6,7). In an
effort to clarify the underlying pathophysiology, several
mutated sodium channels associated with the disorder have
been studied in heterologous expression systems. In all
cases, a reduction in sodium (Na)-current amplitude (INa),
either by a reduction in Na channel expression or through
alterations in channel gating properties (7), is predicted.
Clinically, a reduced Na current is expected to impact on
conduction properties.
An SCN5A mutation, however, is found only in a
minority (15%) of patients (8). Genetic heterogeneity is
also evidenced by linkage to a region on chromosome 3
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(3p22-25), other than the SCN5A locus (3p21), in a family
with the disorder (9).
Genetic heterogeneity also underlies the different sub-
types of the inherited long QT syndrome, in which the
various forms are associated with mutations in multiple
cardiac ion channel genes. In this disorder, clinical and
ECG features display genotype-specific characteristics.
Apart from shedding light on the pathophysiologic mech-
anisms of the various sub-types, this facilitates genetic
screening (10), permits faster genetic testing, and thereby
provides opportunities for earlier initiation of optimal pa-
tient management. It is unclear whether such a genotype-
phenotype relationship exists in BS. In this study, we have
tested whether it is possible to distinguish between SCN5A-
mutation carriers and patients without a sodium channel
mutation on the basis of clinical and ECG criteria.
METHODS
Patient population. Patients diagnosed with BS at the
following three university hospitals were included: Aca-
demic Medical Center, Amsterdam (The Netherlands); the
University of Mu¨nster, Mu¨nster (Germany) and Hoˆpital
Hoˆtel-Dieu, Nantes (France). All tests that were performed
were approved by the medical ethical review committees of
the hospitals involved. Informed consent was obtained from
all patients.
Clinical data, including age at diagnosis, gender, (non)
pharmacologic therapy and family history, were obtained
retrospectively from patient records from the respective
hospitals. Patients without a suspected index event but with
a malignant family history were diagnosed with BS based on
the presence of ECG characteristics consisting of at least
2-mm ST-segment elevation in leads V1 to V3 and (in)com-
plete right bundle branch block morphology. In patients
with aborted cardiac arrest, 1 mm was sufficient. Underlying
(structural) heart disease was excluded by echocardiography,
cardiac catheterization, chest roentgenograms, and exercise
testing. In addition, laboratory tests to exclude (acute)
ischemia and metabolic or electrolyte disturbances were
performed. In total, 77 patients were studied, all of whom
were genetically tested for the presence of an SCN5A
mutation. In order to avoid the predominant effect of any
single mutation, only index patients from each family (and
no other affected family members) were included.
ECG, electrophysiologic measurements, and sodium
channel blocking drugs. The first 12-lead ECG available
in the absence of drugs was analyzed. Heart rate (HR), PQ,
QRS and QT intervals were measured. The QT interval was
corrected using Bazett’s formula (QTc  QT/√RR). The
maximal ST-segment elevation in leads V1 to V3 was
measured.
Baseline electrophysiologic studies (EPS) were performed
in 46 (eight SCN5A-related and 38 non–SCN5A-related) of
77 patients. The His to ventricle interval (HV) and induc-
ibility of ventricular arrhythmias, using up to two extra
stimuli, were registered.
The effect of Na channel blocking drugs was tested in
53 (11 SCN5A-related and 42 non–SCN5A-related) of 77
patients. In three patients, pre-existing ECG abnormalities
were considered too severe for safe testing of these drugs.
Two patients refused the test.
The choice of drug was determined by the availability of
the drug in the hospitals concerned. In 28 patients, ajmaline
(1 mg/kg body weight intravenous at a rate of 10 mg/min)
was used; in 23 patients, flecainide (2 mg/kg body weight
intravenous in 10 min with a maximum of 150 mg) was
used; and in two patients, procainamide (10 mg/kg intra-
venous at a rate of 100 mg/min) was used. The same ECG
measurements as before were performed after administra-
tion of the sodium channel blocking drugs.
Mutation analysis of SCN5A. In all patients, all 28 exons
of SCN5A were amplified by polymerase chain reaction
from DNA isolated from peripheral leukocytes, utilizing
intronic primers. Polymerase chain reaction products were
subjected to single-strand conformation polymorphism
(SSCP) analysis followed by direct sequence analysis of
aberrant conformers (11). In order to increase the probabil-
ity of detecting the presence of any sequence change, SSCP
was carried out at two different temperatures for each exon,
and the size of fragments for SSCP was kept around 300
base pairs (12,13).
Statistical analysis. The Student t test or Mann-Whitney
test was performed, where appropriate, to test for statistical
differences between two mean values. A paired t test was
used for the evaluation of changes in ECG parameters
before and after sodium channel blocking drugs, with p
values of 0.05 considered statistically significant. Propor-
tional differences between groups were analyzed using the
Fisher exact test. Sensitivity, specificity, and receiver-
operator curves were computed to select possible cut points
in the measured values and test for the diagnostic utility of
these.
RESULTS
Patient population and mutation analysis of SCN5A.
The population consisted of a total of 77 patients, 23
SCN5A-related (Table 1) and 54 non–SCN5A-related pa-
Abbreviations and Acronyms
AUC  area under the curve
BS  Brugada syndrome
ECG  electrocardiogram/electrocardiographic
EPS  electrophysiologic studies
HR  heart rate
HV  His to ventricle interval
Na  sodium
SCN5A  pore-forming region (alpha-subunit) of the
human cardiac sodium channel
SSCP  single-strand conformation polymorphism
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tients, respectively. Patient characteristics are summarized
in Table 2. The male:female ratio was not significantly
different between the two groups. Within the whole group,
the age at diagnosis was on average eight years younger in
males compared with females: 45.1  11.2 years versus
53.0  11.7 years (p  0.05). Among SCN5A-mutation
carriers, males were on average 13 years younger than
females: 40.9  9 years versus 53.6  6 years (p  0.05).
Because no further significant differences between males
and females regarding index event and ECG parameters
could be found, these groups were not studied separately in
subsequent analyses. No significant differences in age, fam-
ily history, and index event were observed between mutation
carriers and non-carriers (Table 2).
ECG parameters and electrophysiologic measurements.
The SCN5A-related patients showed a longer PQ interval
on their baseline 12-lead ECG compared with non–
SCN5A-related patients (209  51 ms vs. 163  23 ms
[p  0.0001]; Table 2; Fig. 1A). No significant differences
were observed in HR, QRS duration, QTc interval and
ST-segment elevation (Table 2).
Patients with a mutation in SCN5A were found to have a
significantly longer HV interval, as measured during EPS
(66  13 ms), than patients without an SCN5A mutation
(48  9 ms [p  0.001]) (Table 2; Fig. 1B). Ventricular
fibrillation or polymorphic ventricular tachycardia was in-
duced during programmed electrophysiologic stimulation in
the majority of both SCN5A-related (6 of 8, 75%) and
non–SCN5A-related patients (27 of 38; 71%) who under-
went EPS (pNS). No difference between the HV interval
of symptomatic and asymptomatic patients was observed
(data not shown).
Sodium channel blocking drugs. Both within the total
tested patient population (n  51 [excluding the 2 patients
who were tested using procainamide]) as within the non–
SCN5A-related patient group (n  41), no significant
differences between ajmaline and flecainide could be ob-
served. Within the SCN5A-related patient group, six pa-
tients received flecainide, and four received ajmaline. Also,
no difference could be observed. Procainamide was used in
one SCN5A-related and one non–SCN5A-related patient.
Because previous authors have also reported that they could
not find significant differences in effects of these drugs on
ECG parameters (4), we did not distinguish between the
different drugs in our analysis. No differences in basic
patient characteristics (ECG, index event, and so forth)
were observed between patients challenged and patients not
challenged.
In SCN5A-related patients, Na channel blocking drugs
elicited a significant increase in PQ-interval, QRS-duration,
and ST-segment elevation (Table 3). Similarly, in non–
SCN5A-related patients, administration of Na channel
blocking drugs caused a significant increase in PQ interval,
QRS duration, and ST-segment elevation (Table 3). In
addition, in these patients, HR and QTc interval were also
found to be increased (Table 3).
After administration of Na channel blocking drugs, the
difference in PQ interval between SCN5A-related and
non–SCN5A-related patients was maintained; SCN5A-
related patients had a significantly longer PQ interval than
non–SCN5A-related patients (222 37 ms vs. 195 33 ms
[p  0.05]). In addition, a difference in QRS duration
became evident between SCN5A-related and non–SCN5A-
related patients after drug administration; SCN5A-related
patients had a significantly longer QRS interval than non–
SCN5A-related patients (142  31 ms vs. 118  21 ms [p
 0.05]) (Table 3). No significant differences between the
two groups were observed regarding changes in HR, QTc-
interval, and ST-segment elevation (Table 3).
Interestingly, when comparing the effects of Na channel
blockade between SCN5A-related and non–SCN5A-related
patients, a significantly larger increase in QRS duration in
the former group was observed (38  31 ms vs.18  18 ms
[p  0.05]) (Table 3).
Table 2. Characteristics of Patients With or Without
SCN5A Mutation
Brugada Patients
With SCN5A
Mutation
Brugada Patients
Without SCN5A
Mutation p Value
Total (n) 23 54 —
Gender (m/f) 15/8 44/10 NS
Age (yrs) 45  15 48  11 NS
Family history  11/23 (48%) 24/54 (44%) NS
Index event
VF/VT 6/23 (26%) 15/54 (28%) NS
Syncope 8/23 (35%) 19/54 (35%) NS
Asymptomatic 7/23 (30%) 15/54 (28%) NS
Others* 2/23 (9%) 5/54 (9%) NS
Baseline ECG
(n) 23 54 —
Heart rate (beats/min1) 67  15 71  12 NS
PQ interval (ms) 209  51 163  24 0.0001
QRS duration (ms) 110  24 102  22 NS
QTc interval (ms1/2) 405  31 400  35 NS
ST-segment elevation
(mm)
2.5  1.3 1.9  1.3 NS
Electrophysiologic testing
(n) 8 38 —
VT/VF inducible 6/8 (75%) 27/38 (71%) NS
HV time 66  13 48  9 0.001
Values are mean  SD. *palpitations, unknown.
ECG  electrocardiogram; HV  His to ventricle interval; SCN5A  pore-
forming region of the human cardiac sodium channel; VF  ventricular fibrillation;
VT  ventricular tachycardia.
Table 1. Included SCN5A Mutations
E161K R535X G1319V R1512W
951X G752R S1382I IVS211GA
R367C L867X V1405L G1743E
M369K E1225K G1406R A1924T
1479delK delG 3816 G1502S
From two families two symptomatic index persons were included. Two other
mutations were identified in two unrelated families (proven by haplotype analysis).
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DISCUSSION
In this study we investigated whether a genotype-phenotype
relationship exists in BS. Probing this issue is of interest
because, if such a correlation exists, it might facilitate future
genetic screening in patients with the disorder.
Several mutations linked to BS have been described in
SCN5A, the only gene hitherto linked to the disorder (7). In
vitro studies on implicated mutations have consistently
shown a reduction in Na current either by a decrease in
cell-surface expression or by a reduction of unitary current
secondary to altered biophysical properties (7). This points
toward the likely involvement of altered Na-current char-
acteristics in the generation of both the ST-segment eleva-
tion and ventricular arrhythmias (14). Decreased net inward
(or an increased net outward) current at the end of phase 1
of the cardiac action potential is thought to underlie
epicardial action potential shortening by aggravating the
natural difference in repolarization characteristics of endo-
cardium and epicardium, with resultant ST-segment eleva-
tion in the leads overlying the respective area (5,14). The
resultant electrical heterogeneity in action potential between
epicardial and endocardial layers is expected to be arrhyth-
mogenic (5,14).
The sodium current, however, not only impacts on action
potential duration but also plays an important role in
propagating the action potential. Hence, a reduction in Na
current is also expected to negatively affect conduction
within the heart. As a matter of fact, SCN5A mutations have
Figure 1. (A) PQ interval (ms) on baseline ECG for individual patients. Patients with a pore-forming region (alpha-subunit) of the human cardiac sodium
channel (SCN5A) mutation were found to have a significantly longer PQ interval than patients without an SCN5A mutation. Solid circle  Brugada
syndrome patients with known SCN5A mutation; open circle  mean  SEM; open square  Brugada syndrome patients without known SCN5A
mutation; solid squaremean SEM. (B) His to ventricle interval (HV) time (ms) for individual patients. Patients with an SCN5A mutation were found
to have a significantly longer HV interval than patients without an SCN5A mutation. Solid circle  Brugada syndrome patients with known SCN5A
mutation; open circle  mean  SEM; open square  Brugada syndrome patients without known SCN5A mutation; solid square  mean  SEM.
Table 3. ECG Before and After Class I Antiarrhythmic Drug Challenge
Brugada Patients With
SCN5A Mutation
Brugada Patients Without
SCN5A Mutation p Value
ECG before class I antiarrhythmic drug
(n) 11 42 —
HR (beats/min1) 65  16 72  12* NS
PQ interval (ms) 195  40* 164  27‡ 0.005
QRS duration (ms) 104  26† 100  17‡ NS
QTc interval (ms1/2) 402  28 405  34‡ NS
ST-segment elevation (mm) 2.3  1.6† 1.8  1.0‡ NS
ECG after class I antiarrhythmic drug
(n) 11 42 —
HR (beats/min1) 72  17 76  13* NS
PQ interval (ms) 222  37* 195  33‡ 0.05
QRS duration (ms) 142  31† 118  21‡ 0.05
QTc interval (ms1/2) 426  60 431  40‡ NS
ST-segment elevation (mm) 4.5  1.1† 3.9  1.2‡ NS
Difference in ECG parameters after
class I antiarrhythmic drug
(n) 11 42 —
HR (beats/min1) 10  15 4  12 NS
PQ interval (ms) 26  28 32  21 NS
QRS duration (ms) 38  31 18  18 0.05
QTc interval (ms1/2) 23  64 27  40 NS
ST-segment elevation (mm) 2.2  1.4 2.1  1.3 NS
Values are mean  SD. *p  0.05; †p  0.005; ‡p  0.0001.
ECG  electrocardiogram; HR  heart rate; SCN5A  pore-forming region (alpha-subunit) of the human cardiac sodium
channel.
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also been shown to underlie familial conduction disease
(15,16). It is therefore not unexpected that conduction
disorders are found in BS patients with an SCN5A muta-
tion. Indeed, the prolonged PQ interval at the baseline
ECG observed in our SCN5A-mutation carriers (likely
partially due to the significantly prolonged HV interval in
these individuals) supports the role for Na channel in
conduction (5). Also, though not statistically significant,
Figure 2. (A) Receiver operating characteristic curve comparing sensitivity and specificity of the baseline PQ interval and the presence of an
SCN5A-mutation. Select PQ intervals are indicated. Below are positive predictive value and negative predictive value of various cut points of PQ interval.
(B) Receiver operating curve comparing sensitivity and specificity of the His to ventricle interval (HV) and the presence of an SCN5A mutation. Select HV
intervals are indicated. Below are positive predictive value and negative predictive value of various cut points of HV interval. AUC  area under the curve.
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QRS duration tended to be longer in SCN5A mutation
carriers.
Moreover, these ECG parameters are predictive for the
presence or absence of an SCN5A mutation in BS patients
(Figs. 1 and 2). When a PQ interval of 210 ms or more is
considered to predict the presence of an SCN5A-related
defect, a sensitivity of 48% and specificity of 98% is reached
(Fig. 1A). In parallel, when an HV interval of 60 ms or
more is considered to predict the presence of an SCN5A
mutation, a sensitivity of 88% and a specificity of 82% are
attained (Fig. 1B), with an area under the curve (AUC) of
0.788 for the baseline PQ duration (Fig. 2A) and 0.875 for
the HV interval (Fig. 2B). These two parameters have a
fair-to-good accuracy as a test for predicting the presence or
absence of an SCN5A mutation within the patient group
diagnosed with BS.
Administration of Na channel blocking drugs to BS
patients in general (i.e., whether they are SCN5A-related or
non–SCN5A-related patients) is expected to interfere with
the ion current underlying phase 1 of the cardiac action
potential, thereby exacerbating the ST-segment elevation.
Patients without mutation in SCN5A may also develop
conduction delay after challenge with Na channel blocking
agents, as has been shown both for individuals with and
individuals without BS (17,18). However, patients with an
SCN5A mutation—and, thus, preexistent reduced sodium
current—are expected to be the most susceptible to devel-
opment (or further development) of conduction delay. Our
finding, that SCN5A-mutation carriers show a larger in-
crease in QRS duration after Na-channel blockade than
non–SCN5A-related patients, confirms this hypothesis.
In addition to the PQ interval at baseline, the PQ and
QRS intervals after Na-channel blockade are predictive of
the presence or absence of an SCN5A mutation: both a
PQ-interval of 225 ms and a QRS interval of 140 ms
(abnormal prolongation in both cases) predict the presence
of an SCN5A mutation. The PQ and QRS interval after
Na blocking drugs are less accurate predictors for the
presence or absence of an SCN5A mutation (parameters
with AUC  0.716 [0.543 to 0.889] [p  0.01] and 0.733
[0.549 to 0.916] [p  0.01], respectively [not shown]). It
has been noted before (17) that patients with longer baseline
QRS intervals developed more QRS prolongation upon
flecainide exposure than patients with normal baseline QRS
intervals: a difference in underlying genotype was suggested.
Na-channel blocking drugs, however, do not seem to
differentiate between the two groups of patients when only
the magnitude of the ST-segment elevation is considered
(not shown).
We were also not able to distinguish the two groups on
the basis of other characteristics such as gender, age, family
history, or index event; nor was the inducibility of ventric-
ular fibrillation/ventricular tachycardia different between the
two groups.
The SCN5A mutation is reported to be found in only 15%
of BS patients, and other gene(s) associated with the
disorder have yet to be identified (8). Based on the proposed
mechanism, involving exacerbation of transmural heteroge-
neity in action potential duration, both for ST-segment
elevation and for the genesis of arrhythmias, likely candidate
genes for the disorder are those encoding components
(pore-forming or ancillary) of ion channels active around
phase 1 of the action potential. In particular, this applies to
genes displaying a transmural gradient in expression. Po-
tential candidates include the modulatory subunits of the
sodium channel, the pore-forming and modulatory compo-
nents of the transient outward current, and the L-type
calcium current. However, the disorder may be more com-
plex. The region on chromosome 3 (3p22-25) linked to BS
appears to contain none of these candidates, nor ion channel
components that could represent homologues of these
proteins (9). Furthermore, our study indicates that BS
patients without an SCN5A mutation are expected to have
normal or near-normal cardiac conduction. This suggests
that the as-yet-unidentified causative gene(s) in these pa-
tients (most probably a heterogeneous group) have no
impact (or a smaller impact) on conduction.
Study limitations. Although SSCP conditions for en-
hanced detection of mutations were used, the SSCP analysis
technique is known to be less than 100% sensitive and varies
between 70% and 95% (12,13). Moreover, we analyzed the
coding regions of SCN5A for mutations. One cannot exclude
the possibility of mutations occurring in regions of the gene
other than coding regions. The functional impact has not been
studied for all identified SCN5A mutations; therefore, a causal
relationship in individual patients has not been proved.
Conclusions. In this study we show that the presence of
conduction defects, as evidenced by a prolonged HV inter-
val and PQ interval at baseline, and excessive QRS interval
prolongation after Na-channel blockade are more likely to
be found in BS patients who are carriers of an SCN5A
mutation. This represents the first step toward the identi-
fication of genotype-specific sub-types in BS that, although
other responsible gene(s) have yet to be identified, will
eventually facilitate genetic screening and earlier initiation
of optimal therapeutic strategies.
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